Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425
Rhea-AI Summary
Alpha Cognition (NASDAQ: ACOG) saw accelerating commercial traction for ZUNVEYL at the end of FY25. 4Q25 net product revenue reached $2.5M and FY25 revenue was $10.2M, including $6.8M from ZUNVEYL. Bottles dispensed rose 62% q/q to 4,941, with December at a record 1,859.
Adoption metrics show 729 ordering homes and 865 prescribers, with repeat orders at 82% and repeat writers at 69%. The company ended FY25 with $66.0M cash, which management says funds commercialization into 2027 and supports expected sequential sales growth in 2026.
Positive
- 4Q25 product sales of $2.5M
- FY25 revenue of $10.2M with $6.8M ZUNVEYL sales
- Bottles dispensed +62% q/q to 4,941
- $66.0M cash runway into 2027
- 82% repeat ordering across 729 homes
Negative
- None.
News Market Reaction – ACOG
On the day this news was published, ACOG gained 8.56%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.0% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $140.73M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ACOG gained 3.2% with strong volume. Peers showed mixed moves: MIST up 12.26%, GLSI up 8.2%, SGMO and AGEN modestly higher, while MCRB fell 1.72%. Only one peer appeared in momentum scans, pointing to a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Earnings results | Positive | -4.9% | Reported FY25 revenue of $10.2M and strong ZUNVEYL growth metrics. |
| Mar 13 | Earnings date set | Neutral | -1.7% | Announced timing of Q4 and FY25 earnings release and conference call. |
| Mar 10 | Clinical data plans | Positive | +0.3% | Planned multiple ZUNVEYL clinical data presentations at upcoming conferences. |
| Feb 25 | Study enrollment | Positive | +5.4% | First patient enrolled in BEACON Phase 4 real-world effectiveness study. |
| Feb 18 | Patent issuance | Positive | +11.3% | USPTO issued new patent covering benzgalantamine dosing regimens for ZUNVEYL. |
Recent fundamentally positive updates have often seen mixed to positive price reactions, with one notable selloff on strong earnings metrics.
Over the last several months, Alpha Cognition has built a story around ZUNVEYL’s commercial and clinical progress. On Feb 18, a new U.S. patent extended protection to July 2045, followed by the BEACON Phase 4 study first-patient enrollment on Feb 25. March brought conference presentation plans and fiscal 2025 results showing $10.2M revenue and growing bottle volumes. Today’s coverage update largely reiterates those metrics while emphasizing durability of long-term care adoption and cash runway into 2027.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Aug 22, 2025 provides Alpha Cognition with registered capital-raising flexibility, with disclosed potential dilution from warrants, preferred conversions, and options, but no specific aggregate shelf size stated in the summary.
Market Pulse Summary
The stock moved +8.6% in the session following this news. A strong positive reaction aligns with the article’s emphasis on durable ZUNVEYL traction: 4Q25 net product revenue of $2.5M, FY25 revenue of $10.2M, and a 62% QoQ increase to 4,941 bottles dispensed. The company also reported $66.0M in cash and runway into 2027. With an active Form S-3 shelf, investors have previously faced potential dilution risk from future capital raises.
AI-generated analysis. Not financial advice.
Dallas, Texas--(Newsfile Corp. - April 1, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition exited FY25 with ZUNVEYL showing increasingly durable traction in long-term care, as 4Q25 net product revenue reached
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- ZUNVEYL adoption is becoming durable. 4Q25 sales hit
$2.5M , bottles dispensed rose62% q/q to 4,941, and December reached 1,859. - LTC traction is strengthening with repeat behavior. 729 ordering homes,
82% repeat orders, and 865 prescribers with69% repeat writers support protocol adoption. - ACOG is funded to keep scaling commercialization. Ended FY25 with
$66.0M cash, runway into 2027, and expects continued sequential sales growth in 2026.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290861